Gene · 3568
Papers2,231
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 2,231
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrating Transcriptomic Data and Mendelian Randomization Analyses Reveals Potentially Novel Sepsis-related Targets. | Curr Med Chem | 2026 | 40304330 | PubTator, text mining | PubMed |
| Using biomarkers and independent predictors of therapy response to optimize treatment of uncontrolled severe asthma in the biologic era. | Front Allergy | 2025 | 41584312 | PubTator, text mining | PubMed |
| Type 2 inflammation in chronic obstructive pulmonary disease: A promising treatable trait and practice recommendations. | Chin Med J Pulm Crit Care Med | 2025 | 41551016 | PubTator, text mining | PubMed |
| CAR-T therapy: Advances in respiratory diseases. | Chin Med J Pulm Crit Care Med | 2025 | 41551012 | PubTator, text mining | PubMed |
| Skin-lung axis in the atopic march: The immune link from skin to lungs. | Chin Med J Pulm Crit Care Med | 2025 | 41551010 | PubTator, text mining | PubMed |
| Fulminant Idiopathic Hypereosinophilic Syndrome Presenting with Cardiac, Neurologic and Haematologic Involvement. | Eur J Case Rep Intern Med | 2025 | 41536447 | PubTator, text mining | PubMed |
| Global prevalence of eligibility for biologic therapy in ATS/ERS-defined severe asthma: A systematic review. | World Allergy Organ J | 2025 | 41488544 | PubTator, text mining | PubMed |
| T cell heterogeneity in asthma pathogenesis: from immunological mechanisms to biological targeted therapies. | Front Immunol | 2025 | 41459491 | PubTator, text mining | PubMed |
| Benralizumab: Bringing winds of change to eosinophil-associated diseases. | World Allergy Organ J | 2025 | 41458996 | PubTator, text mining | PubMed |
| Recent Developments in Monoclonal-Antibody-Based Biologic Therapy for Severe Refractory Eosinophilic Asthma. | Antibodies (Basel) | 2025 | 41440490 | PubTator, text mining | PubMed |
| Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma. | Front Immunol | 2025 | 41394834 | PubTator, text mining | PubMed |
| Multi-cohort validation based on coagulation-related genes for predicting prognosis of esophageal squamous cell carcinoma. | Front Immunol | 2025 | 41383582 | PubTator, text mining | PubMed |
| Case Report: A potential novel treatment for drug-induced acute interstitial nephritis: Benralizumab. | Front Immunol | 2025 | 41333468 | PubTator, text mining | PubMed |
| Molecular Pathogenesis and Targeted Therapies in Eosinophilic Granulomatosis with Polyangiitis: An Updated Review. | Int J Mol Sci | 2025 | 41303621 | PubTator, text mining | PubMed |
| Clinical outcomes after switching from omalizumab to anti-IL-5/IL-5R biologics in severe asthma: a retrospective cohort study. | BMC Pulm Med | 2025 | 41299451 | PubTator, text mining | PubMed |
| Eosinophil extracellular traps formation is correlated with cancer prognosis by tumor microenvironment remodeling. | Sci Rep | 2025 | 41249786 | PubTator, text mining | PubMed |
| IL-5 signaling in asthmatic derived fibroblasts exacerbates airway remodeling through ECM dysregulation and apoptosis resistance. | Respir Res | 2025 | 41188935 | PubTator, text mining | PubMed |
| Living with Eosinophilic Granulomatosis with Polyangiitis (EGPA): Podcast of a Patient-Physician Discussion. | Adv Ther | 2025 | 41175322 | PubTator, text mining | PubMed |
| [Clinical remission of severe asthma treated with biological agents in a public hospital in Buenos Aires]. | Medicina (B Aires) | 2025 | 41109276 | PubTator, text mining | PubMed |
| Machine learning-derived genetic risk scores identify IL21 as a predictor of response to omalizumab and dupilumab in asthma. | Front Allergy | 2025 | 41104387 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3568/papers?page=6